Disclosure Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
With reference to the subject cited, please find enclosed the disclosure u/r 40 (9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the half year ended 31.03.2017 Statement Of Grievance Redressal Mechanism For The Quarter Ended 31-03-2017
With reference to the subject cited, please find attached the Statement of Grievance Redressal Mechanism under Regulation 13(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter ended 31.03.2017. Standalone Financial Results, Limited Review Report for December 31, 2016
Concord Drugs Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 2016 Board Meeting Intimation for Results
Concord Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 14, 2017, to consider the following:1. Un - Audited financial results for the quarter ended December 31, 2016.2. Limited Review Report for the quarter ended December 31, 2016. Closure of Trading Window
Concord Drugs Ltd has informed BSE that the trading window in respect of the Companys Securities shall remain closed for all the Directors/Officers/Designed Employees of the Company from the trading hours on February 01, 2017 till close of the trading hours on February 16, 2017 as per the code of Internal Procedure and Conduct for Prevention of Insider Trading adopted by the Company for declaration of unaudited financial results for the quarter ended December 31, 2016. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Concord Drugs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended December 31, 2016
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Change in Company Secretary & Compliance Officer
Concord Drugs Ltd has informed BSE that Ms. Aakanksha Shukla has been appointed as the Compliance officer and Company Secretary of the company in place of Ms. Sonia Bidlan with effect from January 10, 2017. Standalone Financial Results, Limited Review Report for September 30, 2016
Concord Drugs Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Standalone Limited Review for the period ended September 30, 2016 Closure of Trading Window
Concord Drugs Ltd has informed BSE that the trading window in respect of the Companys Securities shall remain closed for all the Directors/Officers/Designed Employees of the Company from the trading hours on November 03, 2016 till close of the trading hours on November 16, 2016 as per the code of Internal Procedure and Conduct for Prevention of Insider Trading adopted by the Company for declaration of unaudited financial results for the quarter ended September 30, 2016.